Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 2;119(47):e2213361119. doi: 10.1073/pnas.2213361119

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 the Author(s). Published by PNAS.

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

PMC Copyright notice

Fig. 1. — Anti-PF4 antibodies in patients with COVID-19 and controls. (A) Anti-PF4 antibodies in healthy donor control patients (HC), hospitalized patients with COVID-19 (Cov-H), patients with COVID-19 visiting the ED (Cov-E), convalescent patients with COVID-19 (Cov-C), and patients hospitalized for severe ARD unrelated to COVID-19. The dotted horizontal line shows the conventional threshold for assay positivity (0.4 OD units). (B) Anti–PF4 antibodies in hospitalized patients with COVID-19 according to their clinical score (WHO score, 4 to 10). (C) Anti-PF4 antibodies in hospitalized patients with COVID-19 admitted or not to the ICU. (D) Antibody isotype of anti-PF4 antibodies in hospitalized patients with COVID-19. The IgM- and IgA-specific assays were not standardized for clinical use. Statistical differences were evaluated by unpaired, two-tailed t tests.